Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma

Authors:

Abstract
Background: We aimed to study the prevalence and prognostic influence of epidermal growth factor receptor (EGFR) and its downstream effectors in synovial sarcoma (SS).Objectives and Methods: The tissue blocks from 30 patients were obtained. Expression of EGFR and phosphatase and tensin homolog (PTEN) were examined by immunohistochemistry, and mutation status of v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) exon 2, V‐raf murine sarcoma viral oncogene homolog B1 (BRAF) exon 15, phosphoinositide‐3‐kinase, catalytic, alpha polypeptide (PI3KCA) exons 9, 20, and PTEN exons 5–9 were analyzed by direct sequencing.Results: EGFR overexpression and PTEN deletion were found in 63.3% and 46.7% of patients. Sequence analysis failed to demonstrate mutations of KRAS and BRAF. However, an E545A point mutation in exon 9 of PI3KCA was found in 2 of the 30 (6.7%) cases and 4 point mutations in exon 5 (E99K, D106N), intro 6 to exon 7 (AATA(G)), and exon 9 (A359T) of PTEN were found in 2 of the 30 (6.7%) cases. PTEN loss was significantly more frequent in cases of trunk tumors, and the overexpression of EGFR was significantly more prevalent in patients who were 35 or older.Conclusions: PTEN deletion was associated with poor survival. J. Surg. Oncol. 2011;103:773–781.
Funding Information
  • Department of Health, Taiwan
  • Center of Excellence for Cancer Research at Taipei Veterans General Hospital (DOH99-TD-C-111-007)
  • Taipei Veterans General Hospital (100DHA0100416)
  • Taiwan Clinical Oncology Research Foundation

This publication has 43 references indexed in Scilit: